To Evaluate The Early-stage Clinical Effect Of OSTEOSET?2DBM In Treating Bone Defect

Objective: Bone transplantation is one of the most important way to treat bone defect. To evaluate the effect of DBM@OSTEOSET , we use the bone substitute to treat patients with bone defect and analyze the early state effect of the clinical results and image data.Methods: From May 2005 to July 2005, 52 patients with bone defect were treated with DBM@OSTEOSET. Each patient was followed up until the bone defect was healed at the 1, 4, 8, 12, 24 week one year and later by X-ray test. We analyzed the clinical data and the recovery of the bone and the complication of the operation and the function of the patients(MSTS).Result: The mean follow-up of all cases is 10 months ( ranged from 8 to 12 months). Six months after operation, there are visible new bone in 75% of all patients and 95% 12 months later. The level of bone reparation is between 60% and 100%. One case is 60% and 38 cases are 90%~100%. 94% of all cases'are recovered. 3 cases had complications(are 5.77% of all patients). There are nankin or plum fluid exud from the wound. But the bacterial culture is negative. There are no other complications (such as, bone defect disunion, pseudoarticulation formation or tumor recur ).Conclusion: It is feasible to use DBM@OSTEOSET to treat bone defect. It can accelerate bone reparation. The function of all cases is good. It can take place of bone autograft to be used in clinical as good implant substitute.